418 related articles for article (PubMed ID: 32636832)
1. Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.
Meng X; Jing R; Qian L; Zhou C; Sun J
Front Immunol; 2020; 11():1046. PubMed ID: 32636832
[TBL] [Abstract][Full Text] [Related]
2. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
Stoiber S; Cadilha BL; Benmebarek MR; Lesch S; Endres S; Kobold S
Cells; 2019 May; 8(5):. PubMed ID: 31108883
[TBL] [Abstract][Full Text] [Related]
3. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
[TBL] [Abstract][Full Text] [Related]
4. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.
Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in CAR-T cell engineering.
Huang R; Li X; He Y; Zhu W; Gao L; Liu Y; Gao L; Wen Q; Zhong JF; Zhang C; Zhang X
J Hematol Oncol; 2020 Jul; 13(1):86. PubMed ID: 32616000
[TBL] [Abstract][Full Text] [Related]
6. Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals.
Fujiwara K; Kitaura M; Tsunei A; Kusabuka H; Ogaki E; Okada N
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33804441
[TBL] [Abstract][Full Text] [Related]
7. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
8. CAR T cell therapy.
Hosen N
Immunol Med; 2021 Jun; 44(2):69-73. PubMed ID: 32693699
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
10. T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors.
Chandler NJ; Call MJ; Call ME
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050044
[TBL] [Abstract][Full Text] [Related]
11. CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.
Bridgeman JS; Ladell K; Sheard VE; Miners K; Hawkins RE; Price DA; Gilham DE
Clin Exp Immunol; 2014 Feb; 175(2):258-67. PubMed ID: 24116999
[TBL] [Abstract][Full Text] [Related]
12. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
14. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
15. The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.
Muller YD; Nguyen DP; Ferreira LMR; Ho P; Raffin C; Valencia RVB; Congrave-Wilson Z; Roth TL; Eyquem J; Van Gool F; Marson A; Perez L; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():639818. PubMed ID: 33833759
[TBL] [Abstract][Full Text] [Related]
16. The making and function of CAR cells.
Zabel M; Tauber PA; Pickl WF
Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
18. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
19. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
[TBL] [Abstract][Full Text] [Related]
20. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
